Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTICIPATE: dexrazoxane for prevention of anthracycline-induced cardiac dysfunction in DLBCL
2023-505377-32-00Phase 3Authorised
- Sponsor
- HOVON
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexrazoxane in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma, T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) and 1 more (2 arms), sponsored by HOVON. Primary endpoints: Incidence of anthracycline-induced cardiac dysfunction and Complete metabolic remission. Planned start Aug 2024; status: authorised.
02
Drugs
dexrazoxane
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomaT-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-505377-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505377-32-00.